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Abstract
TWIST1 is a transcription factor that belongs to the family of basic helix-loop-helix proteins involved in epithelial-to-
mesenchymal transition and invasion processes. The TWIST1 protein possesses oncogenic, drug-resistant, angiogenic and
invasive properties, and has been related with several human tumors and other pathologies. Colorectal cancer is one of the
tumors in which TWIST1 is over-expressed, but its involvement in the clinical outcome of the disease is still unclear. We
tested, by RT-PCR, the expression levels of TWIST1 in normal and tumor paired-sample tissues from a series of 151 colorectal
cancer patients, in order to investigate its prognostic value as a tumor marker. TWIST1 expression was restricted to tumor
tissues (86.1%) and correlated with lymph node metastasis (LNM). Adjusted analysis showed that the expression levels of
TWIST1 correlated with overall survival (OS) and disease-free survival (DFS). Importantly, TWIST1 expression levels predicted
OS specifically at stages I and II. Moreover, patients with stage II tumors and high TWIST1 levels showed even shorter
survival than patients with stage III tumors. These results suggest that TWIST1 expression levels could be a tumor indicator
in stage II patients and help select patients at greater risk of poor prognosis who might benefit from adjuvant
chemotherapy.
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Introduction
Colorectal cancer (CRC) is the second most common cause of
cancer mortality in the developed countries and remains
associated with a high mortality rate [1]. Metastases are the end
result of tumor progression and the most common cause of death
in cancer patients. The genetic bases for metastasis are beginning
to be outlined [2].
Altered functions of several genes that are key players in
embryonic development are related to some steps in oncogenesis,
such as epithelial-mesenchymal transition (EMT). During gastrula-
tion, certain cells from an epithelial-like structure undergo EMT
and migrate to organize the mesoderm embryonic layer. The theory
that tumor cells trigger EMT to allow migration and invasion has
received considerable attention, since several genes involved in
EMT during embryogenesis are turned up during oncogenesis [3].
Yang and co-workers, in a mouse model of breast cancer, identified
genes related to each step of metastasis, particularly those involved
in invasion and intravasation steps in which EMT is a necessary
process [4]. In this context, the transcription factor TWIST1 was
identified as an essential protein in the intravasation step. TWIST1
induces EMT in epithelial cells by activation of SNAI2 transcription
[5], repression of E-cadherin-mediated cell-cell adhesion and
acquisition of mesenchymal markers such as fibronectin and N-
cadherin. Moreover, significant correlation was found between the
expression of TWIST1 and the appearance of invasive lobular
carcinomas [4]. This corroborated a previous study in which the
TWIST1 promoter was much less frequently methylated in invasive
lobular carcinomas than in invasive ductal carcinomas [6].
A number of studies indicate that TWIST1 possesses oncogenic
[7–10], drug-resistant [11–12], angiogenic [13] and invasive
[11,14–17] properties. In addition, TWIST1 over-expression has
been found in tumor tissues such as rhabdomyosarcoma [7],
melanoma [8], pediatric osteosarcoma [18], T-cell lymphoma
[10], gastric [19], prostate [11] and breast carcinoma [4,17,20].
Recently, it has been demonstrated that the TWIST1 protein
overrides oncogene-induced senescence both in murine and
human cancer cells [21].
TWIST1 over-expression in colorectal cancer is associated with
gender and with a poor prognosis factor, such as nodal invasion
[22], but its impact on the clinical outcome of the disease is still not
clear. At the moment, pathological staging is still the most useful
prognostic factor [23]. However, new molecular or clinical
parameters are needed, to improve the current methods for
deciding which patients could benefit from adjuvant chemother-
apy and when.
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We hypothesize that the expression level of TWIST1 in primary
colorectal tumors determines the characteristics of the tumors,
their behavior and their clinical outcome.
Materials and Methods
Patients and samples
The present study was based on a consecutive series of 151
patients undergoing surgery for colorectal cancer and included in
a prospective study. Informed written consent was obtained from
all participants after an explanation of the nature of the study, as
approved by the Research Ethics Board of Puerta de Hierro
Majadahonda University Hospital. All patients were considered
sporadic cases, inasmuch as those with familial adenomatous
polyposis and clinical criteria for hereditary non-polyposis
colorectal cancer (Amsterdam criteria) were excluded.
Tumor and normal colon mucosa (taken at least 3 cm from the
outer tumor margin) were obtained immediately after surgery,
immersed in RNAlaterTM (Ambion Inc, Austin, Texas), snap-
frozen in liquid nitrogen and stored at 280uC until processing. All
patients in the study gave written informed consent.
RNA extraction
RNA was extracted from tumor and normal samples with the
RNeasy Mini Kit (Qiagen Inc., Hilden, Germany), according to
the manufacturer’s protocol. The RNA extracted was quantified
with a NanoDrop ND-1000 Spectrophotometer (nanoDrop
Technologies Inc., Wilmington, Delaware, USA).
Real-Time PCR
TWIST mRNA expression in each sample was measured as a
ratio against the geometric average of three reference housekeep-
ing genes, succinate dehydrogenase complex subunit A (SDHA), TATA
binding protein (TBP) and ubiquitin C (UBC) [24]. The relative
concentrations of the target and the reference genes were
calculated by interpolation, using a standard curve of each gene
plotted from the same serial dilution of cDNA from tumor tissue.
The quantitative mRNA analysis was performed in duplicate.
TWIST1 expression was only determined in tumor tissues, since
normal tissues showed no expression of this gene. An arbitrary
value (0.01), corresponding to half the minimum value detected in
the series, was assigned to the tumors in which TWIST expression
was not detected. SNAI2 expression was calculated as the ratio of
its expression in tumor (T) vs its expression in normal tissue (N).
The primers used were: SDHA-59TGGGAACAAGAGGG-
CATCTG 39 forward (F) and 59CCACCACTGCATCAAATT-
CATG 39 reverse (R); TBP-59TCTGGGATTGTACCGCAGC39
forward (F) and 59CGAAGTGCAATGGTCTTTAGG39 reverse
(R); UBC 59ATTTGGGTCGCGGTTCTTG39 forward (F) and
59TGCCTTGACATTCTCGATGGT39 reverse (R); TWIST1 59
CATGTCCGCGTCCCACTAG 39 forward (F) and 59 TGTCC-
ATTTTCTCCTTCTCTGG 39 reverse (R); SNAI2 59-GGCAA-
GGCGTTTTCCAGAC-39 forward (F) and 59-GCTCTGTTG-
CAGTGAGGGC-39 reverse (R). The annealing temperature in
all cases was 59uC. At the end of the PCR cycles, melting curve
analyses were performed to confirm the generation of the specific
expected PCR product. The PCR products were sequenced in an
ABI PrismTM 377 DNA sequencer apparatus (PE Applied
Biosystems). For the synthesis of cDNA, 400 ng of total RNA
was retro-transcribed, using the Gold RNA PCR Core Kit (PE
Biosystems, Foster City, CA). Real-time PCR was performed in a
Light-Cycler apparatus (Roche Diagnostics, Mannheim, Ger-
many), using the LightCycler-FastStartPLUS DNA Master SYBR
Green I Kit (Roche Diagnostics, Mannheim, Germany).
Clinico-pathological parameters of the patients
The parameters obtained from the medical records of the 151
patients were: age, tumor location, lymph node metastases (LNM)
(evaluated by optical microscopy), pathological stage (assessed by
the tumor-node-metastases classification), tumor histological grade
and the presence of vascular invasion in tumors.
Patients’ treatment and follow-up
Colon cancer patients did not receive neo-adjuvant chemother-
apy (CT). Patients with rectal carcinoma who had received
preoperative treatment with CT and radiotherapy or radiotherapy
alone were excluded, because of the difficulty of finding a suitable
tumor for determining gene expression in these patients’ surgical
samples. Adjuvant treatment based on oxaliplatin (FOLFOX6,
leucovorin 400 mg/m2 IV on day 1 as a 2-hour infusion, followed
by 5-fluorouracil bolus of 400 mg/m2 IV on day 1, followed by
2,400 mg/m2 IV 46-hour infusion and oxaliplatin 100 mg/m2 IV
as a 2-hour infusion on day 1) was administered to the 51 stage-III
patients (29 colon cancer and 22 rectal cancer) without medical
contra-indications who gave their written informed consent.
Radiotherapy was also administered to the 22 rectal tumor cases.
The median age of this subgroup of patients was 69.3 years.
Clinical follow-up after surgery and diagnosis was based on
periodic visits and clinical, biochemical and imaging techniques.
Ultrasonic study was performed when liver function was impaired.
Overall and Disease-Free Survival (OS and DFS) were defined as
the period of time from diagnosis to death and the interval
between diagnosis and first recurrence, respectively.
Statistical analysis
As the distribution of the gene expression values was not
normally distributed (Kolmogorov-Smirnov test), we normalized
the data distribution by using log10 to carry out the statistical
analysis.
The clinico-pathological parameters were contrasted with
TWIST expression data in tumor tissues by the one-way ANOVA
test. The General Linear Model was applied to age and stage in
order to test the possible interaction between the two variables, as
well as their independent value in relation to TWIST1 mRNA
expression levels.
To study OS and DFS, the expression data of TWIST were
divided by tertiles. The expression levels defining the three groups
for the TWIST gene were 0.56 (33%) and 1.7 (66%). DFS analysis
did not include patients at pathological stage IV. The relationship
between the cumulative probability of OS and DFS, as well as
analyzed predictors, was calculated with the Kaplan-Meier method
[25], while significant differences between curves were evaluated
with Mantel’s log-rank test [26]. To identify factors that might be of
independent significance in influencing OS and DFS, multivariate
analysis (Cox proportional risk regression model) was applied [27].
Confounding and interacting variables were analyzed. The model’s
basic assumptions (proportional hazards) were evaluated. In all
statistical tests two-tailed p values # 0.05 were considered
statistically significant. Statistical analyses were performed with
SPSS 13.0 statistical software (SPSS Inc, Chicago, IL).
Results
TWIST1 expression is confined to tumor tissues in human
colorectal cancer and is up-regulated in patients with
lymph node metastasis
The analysis of TWIST1 expression levels in tumor and normal
matched tissues from 151 patients with colorectal cancer showed
TWIST Prognosis Marker in Colon Cancer
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that the expression of TWIST1 is restricted to the tumor mass. It
was never detected in any normal tissues. Of 151 tumor samples
tested, TWIST1 was detected in 130 cases (86.1%).
A statistical association between high levels of TWIST1 in tumor
tissues and lymph node metastasis (LNM) was observed (p= 0.016),
while only a trend to statistical association was found for age
(p= 0.052) and tumor stage (p= 0.07) (Table 1). Though this
suggests a possible interaction between the two variables, the
statistical General Linear Model showed no interaction between
age and tumor stage, as well as, an independent relationship for
age and TWIST1 expression levels, p= 0.031. The median and
range of lymph node harvesting counts were: 9 (0–34).
No statistical associations between TWIST1 expression levels
and the other pathological variables analyzed were found
(summarized in Table 1).
TWIST1 mRNA levels correlate with the transcriptional
activity of the protein
To ensure that TWIST1 mRNA levels detected in each sample
correlate with protein activity, the mRNA levels of Snai2 were
measured in the 130 patients in whom TWIST1 was previously
detected. SNAI2 is another transcription factor involved in the
EMT, whose transcription is directly regulated by TWIST1, as has
been recently demonstrated [5]. As expected, a direct correlation
between TWIST1 and SNAI2 mRNA levels (Pearson correlation
coefficient r= 0.41, P,0.001) was found, suggesting that there is a
correlation between TWIST1 mRNA levels and protein activity
(Fig 1A).
TWIST1 expression level is related to overall survival
The series was followed for a mean of five years (range of patient
follow-up: 1–82 months). During this period, 54 recurrences
(35.8%) were recorded and 50 patients (33.1%) died, with the five-
year OS for the series at 62.4% (95% CI, 53.8%–70.98%). To
carry out survival analysis, the series was divided by tertiles on the
basis of TWIST1 expression levels. Thus, patients were classified
with low, medium or high levels of TWIST1 expression. A
statistical difference was observed in OS for the expression of
TWIST1 (p,0.001): the five-year OS for each group was 79%
(95% CI, 67%–91%) for those patients with low expression levels;
66.6% (95% CI, 51.9%–81.3%) for patients with medium
expression levels; and 40.6% (95% CI, 24.6%–56.6%) for patients
with high expression levels (Fig. 1B). Since no statistical differences
were found for OS in patients with low or medium levels of
TWIST1 expression and both groups behaved quite similarly (see
Fig. 1B), unlike patients with high TWIST1 expression levels, these
two categories were grouped. Therefore, further studies were
carried out with only two categories: patients with low (the former
low plus medium levels) or high expression levels of TWIST1. No
changes in the correlation previously observed between OS and
TWIST1 expression levels were found with this new classification.
Thus, five-year OS for patients with high expression levels was the
above-mentioned 40.6% (95% CI, 24.6%–56.6%), versus 72.9%
(95% CI, 63.3%–82.5%) in those cases with low expression levels
(p,0.001) (Fig. 1C).
Since, according to this result, the expression levels of TWIST1
in human colorectal cancer could be considered a poor prognosis
factor, we were interested in the clarification of its possible
prognosis value at each different colorectal tumor stage. The
number of patients with low expression levels was: 9 for stage I, 51
for stage II, 34 for stage III and 6 for stage IV. Equally, the
number of patients with high expression levels was: 5 for stage I,
24 for stage II, 17 for stage III and 5 for stage IV. Interestingly, the
Kaplan-Meier analysis showed that the expression levels of
TWIST1 correlated with OS, but only in stages I and II.
Therefore, five-year OS for stage I was 33.3% (95% CI, 0%–
86.65%) in patients with high levels versus 83.3% (95% CI, 53.5–
100%) in patients with low expression levels (p= 0.006); for stage
II, it was 54.53% (95% CI, 28.29%–80.77%) in patients with high
expression levels versus 90.92% (95% CI, 82.42–99.42%) for
patients with low expression levels (p= 0.002). In contrast, the
Kaplan-Meier curves in stages III or IV were similar for both
groups, i.e. patients with high and low TWIST1 expression levels,
with no statistical differences observed (Fig. 1D).
Because the different treatment protocols may affect OS and
mimic the prognosis value of TWIST1, we also analyzed the
prognosis value of TWIST1 at each different treatment subgroup
(Fig 2). Four groups of treatment were identified. In the first group,
67 patients underwent only surgery. All of these were colon cancer
cases with tumors at stages I or II (note that there were 6 patients
with stage IV colon tumors and 8 patients with stage I or IV rectal
tumors who also underwent only surgery, but were not considered
in this analysis in order to achieve greater homogeneity for this
study). Five-year OS for patients with high TWIST1 expression
was 54.5% (95% CI; 81.5%–27.4%) versus 89.6% (95% CI;
Table 1. Associations between the expression of TWIST gene
in tumor tissues and clinico-pathological characteristics.
Characteristics Total (%) Expression of TWIST
Median/minimum/
maximum p a
Patients 151
Median age 71
,71 63 (41.72%) 0.92/0.001/10.33 0.052
.71 88 (58.28%) 1.04/0.01/56.90
Gender
Male 96 (63.58%) 1.04/0.01/56.90 NS
Female 55 (36.42%) 0.88/0.01/23.63
Tumor side
Colon 102 (67.55%) 0.91/0.01/56.90 NS
Rectum 49 (32.45%) 1.67/0.01/22.78
Stage
I 14 (9.27%) 1.53/0.01/3.89 0.074
II 75 (49.67%) 0.89/0.01/56.90
III 51 (33.77%) 1.16/0.01/22.78
IV 11 (7.28%) 1.67/0.44/23.66
Vascular invasion
Yes 63 (41.72%) 0.96/0.01/56.90 NS
No 88 (58.28%) 1.00/0.01/23.63
Lymph node
metastases
Positive 62 (41.06%) 1.19/0.01/23.63 0.016
Negative 89 (58.94%) 0.94/0.01/56.90
Tumor differentiation
Good 41 (27.15%) 0.82/0.01/7.04 NS
Moderate 77 (50.99%) 1.22/0.01/22.78
Poor 33 (21.85%) 1.67/0.01/56.90
ap is calculated by the ANOVA test.
NS: Not significant.
doi:10.1371/journal.pone.0018023.t001
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99.4%–79.8%) in patients with low expression levels (p= 0.001). In
a second group, 19 patients underwent radiotherapy as well as
surgery: all of these were patients with stage II rectal tumors,
except for two at stage I. In this group, five-year OS for patients
with tumors with high expression levels was 48.6% (95% CI;
92.9%–4.3%) versus 90% (95% CI; 100%–71.6%) in patients with
low expression levels (p= 0.09). No differences in OS according to
TWIST1 expression levels were observed in the two remaining
groups. One of these consisted of 29 patients who received
chemotherapy after surgery (all were patients with stage III colon
cancer tumors). The other consisted of 22 patients who received
chemotherapy plus radiotherapy, as well as surgery (all of these
were patients with stage III rectal cancer tumors). Again, the only
clear differences in OS were found in the group considered to have
good prognosis.
Univariate analysis was performed to determine the influence of
TWIST expression and the clinico-pathological parameters in OS.
Variables which could be considered statistically supported factors
in OS prediction were: LNM, stage, treatment protocols and
TWIST1 expression levels (Table 2). In the multivariate Cox’s
regression model for OS, the variables that showed an indepen-
dent prognostic factor were: LNM HR 4.02 (95% CI; 2.21–7.3)
(p,0.001) and TWIST1 expression levels HR 2.73 (95% CI; 1.54–
4.84) (p = 0.001) (Table 2). Because LNM and tumor stage are
linearly dependent covariates (tumor stages I and II are LNM
negatives and tumor stage III and, probably, the vast majority at
tumor stage IV are LNM positives), the variable tumor stage was
not included in the multivariate analysis.
Since our results suggested that TWIST1 expression levels have
prognosis value at early stages I and II (both LNM negatives), we
repeated the Cox’s regression models, stratifying the series for their
LNM status. This analysis confirmed that TWIST1 expression
levels have prognosis value only in patients without lymph node
metastasis (Table 3).
TWIST1 expression levels are related to Disease-Free
Survival
No clear difference was observed for TWIST1 expression levels
and DFS after Kaplan-Meier analysis: five-year DFS for patients
with low TWIST1 expression levels was 67.58% (95% CI;
57.25%–77.9%) vs 54.75% (95% CI; 39.07%–70.43%) in patients
with high expression levels (Fig. 3A). However, this analysis
performed in the series stratified by stage showed a correlation
between TWIST1 expression levels and DFS in stage I: 88.9%
(95% CI; 68.36%–100%) in patients with low expression levels vs
33.3% (95% CI; 0%–86.6%) in patients with high expression
levels (p= 0.02). No correlation was found in stages II and III
(Fig. 3B).
Variables which could be considered statistically supported
factors in DFS prediction, according to the Cox’s model, were
LNM (p,0.001) and stage (p= 0.046). However, the multivariate
Cox’s regression model included TWIST1 expression levels, HR
1.99 (95% CI, 1.05–3.82) (p= 0.036) and gender, HR 2.07 (95%
CI; 1.04–4.15) (p= 0.038) as independent prognosis factors for
DFS, as well as the variable LNM, HR 3.4 (95% CI; 1.83–6.32)
(Table 4).
Figure 1. Kaplan-Maier OS curves and TWIST1 activity. A, Relation between expression levels of TWIST1 and SNAI2 genes, logR(T/N), in
patients in which TWIST1 was previously detected. TWIST1 and SNAI2 expression directly correlates in human colon cancer, Pearson correlation
coefficient r= 0.41 (P,0.001). Kaplan-Meier curves and p values for OS for TWIST1 expression levels: B, in the series distributed by tertiles: low,
medium and high. C, grouping tertiles: low and medium as low. D, stratifying the series by tumor stage.
doi:10.1371/journal.pone.0018023.g001
TWIST Prognosis Marker in Colon Cancer
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18023
TWIST1 expression in patients with stages II and III
tumors and Overall Survival
We compared the survival curves between patients with stage
III tumors and patients with stage II tumors, dividing this group in
two categories: those with low TWIST1 expression levels and those
with high expression levels (Fig. 4A). Unlike patients with stage III
tumors, none of these patients received adjuvant chemotherapy. In
this analysis, we did not observe difference at five-year OS
between patients at stage III, 44.04% (95% CI; 28.98%–59.09%),
and patients at stage II with high TWIST1 expression levels,
54.53% (95% CI, 28.29%–80.77%). However, the difference was
clear when patients in stage II expressing low TWIST1 levels were
compared with stage III patients (p,0.001). Moreover, by the end
of the study (82 months) cumulative survival was higher in patients
with stage III tumors, 44.04% (95% CI; 28.98%–59.09%), than in
patients with stage II tumors and high TWIST1 expression levels,
40.9% (95% CI; 10.52%–71.28%). This analysis was repeated,
taking into account only colon cancer cases, not rectal cancer
cases, in order to achieve greater homogeneity for the study.
Again, the behavior of the different groups was very similar
(Fig. 4B), confirming that this analysis was not affected by tumor
location or treatment protocols, since all of the patients with stage
III tumors were treated with chemotherapy before surgery.
Figure 2. Kaplan-Maier OS curves regarding treatment protocols. Kaplan-Meier curves and p values for OS for TWIST1 expression levels in
each one of the treatment groups. CT, chemotherapy; RT, radiotherapy.
doi:10.1371/journal.pone.0018023.g002
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Discussion
We examined the expression of TWIST1 in the normal and
tumor tissues of a large series of 151 colorectal cancer patients.
TWIST1 expression was restricted to tumor tissues, indicating that
it could be a tumor marker. Moreover, its expression was
associated with certain pathological parameters linked to poor
prognosis, such as LNM, which corroborates a publication in this
field [22].
In our view, the most significant result was that TWIST1
expression levels gave an independent prognostic factor, for both
OS and DFS. Indeed, the detailed analysis of the correlation
between TWIST1 expression levels and OS and DFS, at each
tumor pathological stage, showed an interaction between these
two variables, pathological tumor stages and TWIST1 expression.
Therefore, for OS, TWIST1 was a prognostic factor only at stages
I and II, losing its prognostic value in advanced stages (III and IV).
In a similar way, the study showed TWIST1 as a prognostic factor
for DFS only in stage I, losing this correlation in stages II and III.
The results found in our study have not been described in the
literature on TWIST1 expression and patients’ prognosis.
Although negative results have been reported between TWIST1
expression and patient survival [28] in colon cancer cases, there
are several publications that support this relationship, when
analyzing the evolution of patients and mRNA TWIST1 levels in
colon cancer [29] and cervix carcinoma [30]. The expression of
TWIST1 and other functionally related genes, such as E-Cad,
SNAIL, SLUG and HIF-1a, has also been studied in relation to
survival in several tumor types, such as esophageal cancer [31],
head and neck [32,33] and bladder [34] carcinoma, with these
relationships increasing when any of these genes are also
overexpressed, as well as TWIST1. It is possible that a stage-by-
stage analysis in some of these series would also provide results
similar to ours. It would be reasonable to think that, if colon
cancer develops by following steps [35], and tumor progression in
these steps is caused by the accumulation of mutations in
oncogenes and tumor suppressor genes, the accumulation of these
at more advanced stages of disease could mimic the effects of
overexpression of TWIST1 on patients’ survival.
Currently, the use of adjuvant chemotherapy for all patients
with stage III colon cancer after resection is part of standard
treatment around the world. However, the controversy about
adjuvant treatment in stage II CRC is currently unresolved. The
IMPACT B2 study pooled results from five trials in Dukes B2
colon cancer patients. This study did not show any benefit in five-
year overall survival: results were 80% in the control group and
82% in the 5-fluorouracil and leucovorin group [36]. Nevertheless,
the four NSABP adjuvant studies showed decreased death risk
with adjuvant treatment, similar to the benefit obtained in stage C
[37]. Another Dutch study reported a beneficial effect of 5-
fluorouracil and levamisol adjuvant therapy in stage II patients,
similar to the expected benefit in stage III ones [38]. Anyway,
despite the lack of data, there is growing acceptance of an informal
classification system, stratifying stage II patients by risk on the
basis of clinical data, as a guide for deciding whether to use
adjuvant therapy. Therefore, in stage II patients with high clinico-
pathological risk (intestinal obstruction, perforation, tumor
Table 2. Unadjusted and adjusted analyses of the association between TWIST expression and overall survival of colon cancer
patients.
Variable Category Unadjusted analysis Adjusted analysis
HR (95% CI) p Value HR (95% CI) p Value
Age at diagnosis ,71 vs .71 0.775 0.44–1.37 0.38
Sex of patients Male vs female 1.53 0.82–2.86 0.18
Lymph node metastases Yes vs No 3.99 2.2–7.24 ,0.001 4.02 2.21–7.3 ,0.001
Vascular invasion Yes vs No 1.66 0.94–2.93 0.079
Stage II vs I 0.91 0.26–3.18 0.87
III vs I 3.06 0.92–10.2 0.068
IV vs I 35.09 7.89–155.9 ,0.001
Histological grade 2 vs 1 1.49 0.76–2.94 0.25
3 vs 1 1.02 0.42–2.5 0.96
Tumor side Rectum vs colon 1.41 0.79–2.50 0.24
TWIST expression High vs low 2.72 1.53–4.82 0.001 2.73 1.5–4.84 0.001
Treatment Protocols CT vs surg 2.18 1.08–4.39 0.029
RT vs surg 0.77 0.26–2.25 0.63
CT + R vs surg 2.19 1.04–4.58 0.038
The blank cells correspond to variables that showed no independent relationship with OS in the adjusted analysis. CT, chemotherapy; RT, radiotherapy.
doi:10.1371/journal.pone.0018023.t002
Table 3. Analysis of the association between TWIST
expression and overall survival of colon cancer patients by
lymph node metastases.
Variable Category LNM positives LNM negatives
HR
(95%
CI) p Value HR
(95%
CI) p Value
Age at
diagnosis
,71 vs
.71
2.28 0.87–
5.97
0.09 0.78 0.38–
1.62
0.5
TWIST
expression
High vs
low
6.57 2.31–
18.7
,0.001 1.84 0.88–
3.84
0.1
doi:10.1371/journal.pone.0018023.t003
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Figure 3. Kaplan-Maier DFS curves. Kaplan-Meier curves and p values for DFS for TWIST1 expression levels: low (formed by medium and low
tertiles) and high: A, in the entire series, except patients with stage IV tumor; B, at each tumor stage except stage IV.
doi:10.1371/journal.pone.0018023.g003
Table 4. Unadjusted and adjusted analyses of the association between TWIST expression and disease-free survival of colon cancer
patients.
Variable Category Unadjusted analysis Adjusted analysis
HR (95% CI) p Value HR (95% CI) p Value
Age at diagnosis ,71 vs .71 0.56 0.3–1.07 0.057 1.68 0.88–3.19 0.112
Sex of patients Male vs female 1.895 0.96–3.76 0.067 2.07 1.04–4.15 0.038
Lymph node metastases Yes vs No 3.57 1.94–6.57 ,0.001 3.4 1.83–6.32 ,0.001
Vascular invasion Yes vs No 1.69 0.93–3.09 0.087
Stage II vs I 0.94 0.27–3.25 0.9
III vs I 3.39 1.02–11.28 0.046
Histological grade 2 vs 1 1.91 0.93–3.93 0.08
3 vs 1 0.65 0.2–2.07 0.46
Tumor side Rectum vs colon 0.84 0.45–1.6 0.6
TWIST expression High vs low 1.54 0.83–2.84 0.17 1.99 1.05–3.82 0.036
Treatment Protocols CT vs surg 4.52 2.16–9.43 ,0.001
RT vs surg 1.44 0.51–4.03 0.49
CT + RT vs surg 3.15 1.35–7.38 0.008
The blank cells correspond to variables that showed no independent relationship with OS in the adjusted analysis. CT, chemotherapy; RT, radiotherapy.
doi:10.1371/journal.pone.0018023.t004
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adherence, poor differentiation, vascular or lymphatic invasion),
adjuvant therapy can reasonably be offered.
The analysis performed to study the behavior of TWIST1
overexpression in relation to OS in subgroups of patients who
received similar treatment protocols showed no significant
differences, except for patients who had received no adjuvant
therapy and thus patients in early stages. This supports the results
found in the analysis of the complete series by stages, which
showed that TWIST1 is a discriminating factor in early stages of
the disease.
Although, at stage III, TWIST expression did not differ in terms
of OS and DFS, it could be relevant that the OS of stage-II patients
with high TWIST expression was similar to that observed in patients
at stage III. Moreover, the cumulative OS at the end of the study for
this group of patients was higher than the cumulative OS in patients
at stage II and high expression levels of TWIST1. These preliminary
observations could support the idea of TWIST1 expression as a
tumor indicator at stage II, which could help select patients at
greater risk who might benefit from adjuvant chemotherapy.
There is no biological explanation that justifies patients with
stage I tumors and high TWIST1 expression levels showing shorter
cumulative survival, 33.3% (95% CI, 0%–86.65%), than the same
category with stage II tumors, 54.53% (95% CI, 28.29%–80.77%).
These results obtained from Kaplan-Meier analyses at each tumor
stage may seem an artefact, due to the low number of samples in a
group, such as stage I. However, our conclusions are supported by
the results obtained from another approach, i.e. LNM status or
treatment protocols in OS, where the study was not affected by the
number of samples and showed that in both cases TWIST1 mRNA
expression levels have prognosis value only in early stages.
Cancer cells that are undergoing Epithelial-Mesenchymal
Transition usually show deregulation of various genes. For instance,
up-regulation of SNAIL1, ZEB1, ZEB2 or E12 in epithelial cells
represses E-cadherin expression and induces EMT in several
carcinomas [39–46]. Recently, the transcription factor TWIST1
has been added to the list of proteins that trigger EMT [4]. Yang et
al. suggested that the expression of TWIST1 is essential in the
intravasation step during the metastatic process. Expression of
TWIST1 by tumor cells might enhance the intravasation steps of
metastasis. In this case, tumors expressing TWIST1 would display
more aggressive behavior and trigger the intravasation steps, even
though no visible metastases are observed.
We show that TWIST1 expression levels may be an indepen-
dent prognostic factor in patients with CRC. It may be well used
in stage II to identify sub-groups of patients at high risk with a poor
prognosis who might benefit from adjuvant chemotherapy.
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Figure 4. Kaplan-Maier OS curves in stages II and III. Kaplan-Meier curves and p values for OS at tumor stage III, tumor stage II with low TWIST1
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